NO20075721L - New crystalline atorvastatin hemicalcium salt polymorph form - Google Patents

New crystalline atorvastatin hemicalcium salt polymorph form

Info

Publication number
NO20075721L
NO20075721L NO20075721A NO20075721A NO20075721L NO 20075721 L NO20075721 L NO 20075721L NO 20075721 A NO20075721 A NO 20075721A NO 20075721 A NO20075721 A NO 20075721A NO 20075721 L NO20075721 L NO 20075721L
Authority
NO
Norway
Prior art keywords
polymorph form
atorvastatin hemicalcium
hemicalcium salt
new crystalline
crystalline atorvastatin
Prior art date
Application number
NO20075721A
Other languages
English (en)
Inventor
Peter Kotay Nagy
Gyula Simig
Kalman Nagy
Jozsef Barkoczy
Zsuzsanna Szent-Kirallyi
Ferenc Bartha
Zoltan Katona
Gyorgyi Vereczkeyne Donath
Norbert Nemeth
Gyorgy Ruzsics
Original Assignee
Egis Gyogyszergyar Nyilvanosan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0500370A external-priority patent/HU0500370D0/hu
Priority claimed from HU0600120A external-priority patent/HUP0600120A3/hu
Application filed by Egis Gyogyszergyar Nyilvanosan filed Critical Egis Gyogyszergyar Nyilvanosan
Publication of NO20075721L publication Critical patent/NO20075721L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

Foreliggende oppfinnelse angår en ny krystallinsk polymorf B-52 form av atorvastatin hemikalsiumsalt [A[(3R, 5R)-7-[3-fenyl-4-[(fenylkarbamoyl]-2-(4-fluorfenyl)-5-(l-metyletyl)-l H-pyrrol-1 -yl]-3,5-dihydroksy-heptansyrekalsiumsalt (2:1)], medisinske preparater som inneholder den nye polymorf formen, fremgangsmåter for fremstilling derav og anvendelse av den nye polymorfe fonnen for fremstilling av medisinske produkter.
NO20075721A 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form NO20075721L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0500370A HU0500370D0 (en) 2005-04-08 2005-04-08 New crystalline atorvastatin hemicalcium polimorph
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form

Publications (1)

Publication Number Publication Date
NO20075721L true NO20075721L (no) 2008-01-04

Family

ID=89986585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075721A NO20075721L (no) 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form

Country Status (13)

Country Link
US (1) US20090215855A1 (no)
EP (1) EP1868993B1 (no)
JP (1) JP5523699B2 (no)
BG (1) BG66035B1 (no)
CZ (1) CZ2007772A3 (no)
EA (1) EA014079B1 (no)
HK (1) HK1117141A1 (no)
IL (1) IL186499A (no)
NO (1) NO20075721L (no)
RO (1) RO200700700A8 (no)
RU (1) RU2409563C2 (no)
SK (1) SK288276B6 (no)
WO (1) WO2006106372A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100023059A (ko) 2005-12-13 2010-03-03 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법
EP1986997A4 (en) * 2006-02-22 2010-09-15 Matrix Lab Ltd NEW CRYSTALLINE HEMI-CALCIUM FORM OF ATORVASTATIN
EP2522348B1 (en) * 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Atorvastatin-containing coated preparation
KR20120011249A (ko) * 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
BR9609872A (pt) * 1995-07-17 1999-03-23 Warner Lambert Co Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino
CN1535139A (zh) * 2000-11-03 2004-10-06 ������ҩ��ҵ���޹�˾ 阿伐他丁半钙形式ⅶ
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
MXPA03005879A (es) * 2000-12-27 2003-09-10 Ciba Sc Holding Ag Formas cristalinas de atorvastatina.
JP2005519076A (ja) * 2002-02-15 2005-06-30 テバ ファーマシューティカル インダストリーズ リミティド アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
CA2475123A1 (en) * 2002-02-19 2003-08-28 Teva Pharmaceutical Industries Ltd. Desolvating solvates of atorvastatin hemi-calcium

Also Published As

Publication number Publication date
WO2006106372A1 (en) 2006-10-12
EA014079B1 (ru) 2010-08-30
HK1117141A1 (en) 2009-01-09
RO123642B1 (ro) 2015-07-30
CZ2007772A3 (cs) 2008-02-27
SK288276B6 (sk) 2015-06-02
JP5523699B2 (ja) 2014-06-18
BG109992A (bg) 2008-05-30
RO200700700A8 (ro) 2015-07-30
US20090215855A1 (en) 2009-08-27
EP1868993B1 (en) 2014-04-30
EP1868993A1 (en) 2007-12-26
WO2006106372A8 (en) 2008-03-13
JP2008534669A (ja) 2008-08-28
SK51252007A3 (sk) 2008-07-07
IL186499A (en) 2016-04-21
IL186499A0 (en) 2008-01-20
RU2007140797A (ru) 2009-05-20
RU2409563C2 (ru) 2011-01-20
EA200702191A1 (ru) 2008-04-28
BG66035B1 (bg) 2010-11-30

Similar Documents

Publication Publication Date Title
YU56803A (sh) Pripremanje nekristalinskog atorvastatin-kalcijuma
DE60239425D1 (de) Kalziumatorvastatin enthaltende arzneiformulierung
HUP9901687A2 (hu) Kristályos (III) formájú (R-(R*,R*)-2-(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-((fenil-amino)-karbonil)-1H-pirrol-1-heptánsav hemi kálcium-só (Atorvastatin) és ezt a vegyületet tartalmazó gyógyszerkészítmények
AR003458A1 (es) Forma cristalina de atorvastatina o hidrato de la misma y composicion farmaceutica que la comprende.
HRP20031039A2 (en) Crystalline forms of 'r-(r*,r*)^-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl^-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
HUP0301325A2 (hu) Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
NO20075721L (no) New crystalline atorvastatin hemicalcium salt polymorph form
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
CA2508871A1 (en) Crystalline form f of atorvastatin hemi-calcium salt
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
UA93202C2 (ru) Полиморфная форма кристаллической гемикальциевой соли аторвастатина
KR100878140B1 (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
WO2009007856A3 (en) Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
DE69930621D1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
ES2316957T3 (es) Composicion medicinal para tratar la infeccion con staphylococcus aureus resistente a farmacos.
AR045654A1 (es) Formas cristalinas de acido r-(r*,r*)-2-(4- fluorofenil) - , dihidroxi - 5-(1- metiletil)- 3- fenil- 4-( fenilamino) - carbonil- 1h- pirrol-1- heptanoico
HUP0600120A2 (en) New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
EP2117516A2 (en) Stable atorvastatin formulations
RU2004100459A (ru) Способ введения гемостатических лекарственных препаратов при эндовидеохирургических операциях

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application